European Journal of Neurology 2024 Sep:31 Suppl 2:e16434. doi: 10.1111/ene.16434. Robyn-Jenia Wilcha, Shazia K Afridi , Piero Barbanti, Hans Christoph Diener, Tim Patrick Jürgens, Michel Lanteri-Minet, Christian Lucas, Jerôme Mawet, Xavier Moisset, Antonio Russo, Simona Sacco, Alexandra J Sinclair, Marja-Liisa Sumelahti , Cristina Tassorelli, Peter J Goadsby Abstract Background: Varied responses to acute migraine medications
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurology 2024 Sep 16:e243043. doi: 10.1001/jamaneurol.2024.3043. Online ahead of print. Stewart J Tepper, David W Dodick, Michel Lanteri-Minet , David Dolezil , Raquel Gil-Gouveia, Christian Lucas, Karolina Piasecka-Stryczynska, Gyöngyi Szabó, Daniel D Mikol, Mahan Chehrenama, Denise E Chou, Yiping Yang, Gabriel Paiva da Silva Lima Abstract Importance: Patients with chronic migraine and medication
SPIDOL study protocol for the assessment of intrathecal ziconotide antalgic efficacy for severe refractory neuropathic pain due to spinal cord lesions
Trials 2024 Sep 7;25(1):595. doi: 10.1186/s13063-024-08387-0. Andrei Brinzeu, Julien Berthiller, Nathalie Perreton, Fabien Subtil, Caroline Gervaise, Jacques Luaute, Patrick Mertens; SPIDOL Study Group Collaborators SPIDOL Study Group: Michel Lanteri-Minet, Brigitte Perrouin Verbe, Bechir Jarraya, Philippe Menei, Jimmy Voirin, Jean-Marie Regis, Kevin Buffenoir, Marc Lefort, Denys Fontaine, Jean Luc Barat Abstract Rationale: Central neuropathic pain resulting from spinal
Disability in migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study
Cephalalgia 2024 Aug;44(8):3331024241274343. doi: 10.1177/03331024241274343. Zaza Katsarava, Dawn C Buse, Elizabeth Leroux, Michel Lanteri-Minet, Fumihiko Sakai, Manjit S Matharu, Aubrey Manack Adams, Karen Carr, Kristina M Fanning, Richard B Lipton Abstract Background: Few studies of migraine have evaluated migraine disability across multiple countries using the same methodology. Methods: This cross-sectional, web-based
Characterizing barriers to care in migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) study
The journal of headache and pain 2024 Aug 19;25(1):134. doi: 10.1186/s10194-024-01834-y. Michel Lanteri-Minet, Elizabeth Leroux, Zaza Katsarava, Richard B Lipton, Fumihiko Sakai, Manjit Matharu, Kristina Fanning, Aubrey Manack Adams, Katherine Sommer, Michael Seminerio, Dawn C Buse Abstract Objective: To assess rates of traversing barriers to care to access optimal clinical outcomes
Somatotopy of the sensory thalamus: inputs from directional deep brain stimulation in pain patients
Annals of Clinical and Translational Neurology 2024 Jun 11.doi: 10.1002/acn3.52067. Aurelie Leplus, Petru Isan, Anne Balossier, Sarah Mouffok, Anne Donnet, Theodore Papadopoulo, Michel Lanteri-Minet, Jean Regis, Denys Fontaine Abstract Objective: The sensory ventroposterior (VP) thalamic nuclei display a mediolateral somatotopic organization (respectively head, arm, and leg). We studied
Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study
Neurology 2024 May;102(10):e209349. doi: 10.1212/WNL.0000000000209349. Epub 2024 Apr 26. Uwe Reuter, Peter J Goadsby, Michel D Ferrari, Gabriel Paiva Da Silva Lima, Subhayan Mondal, Jawed Kalim, Fatima Hasan, Shihua Wen, Michal Arkuszewski, Shaloo Pandhi, Tracy Stites, Michel Lanteri-Minet Abstract Background and objectives: The LIBERTY study assessed the efficacy and safety of erenumab
Triptan use in elderly over 65 years and the risk of hospitalization for serious vascular events
The Journal of Headache and Pain 2024 Apr 26;25(1):68. doi: 10.1186/s10194-024-01770-x. Phuong Thao Tran, Maryse Lapeyre-Mestre, Baricault Berangere, Michel Lanteri-Minet, Aurore Palmaro, Anne Donnet, Joëlle Micallef Abstract Background: Several studies have focused on the use of triptan and the risk of acute vascular events but the
Patient Sex in Prescribing CGRP Receptor Antagonists for Migraine
JAMA Neurology JAMA Neurol. Published online February 26, 2024. doi:10.1001/jamaneurol.2023.5835 Michel Lanteri-Minet; Shuu-Jiun Wang; Paolo Martelletti To the Editor In a recent JAMA Neurology Viewpoint,1 Porreca and Dodick raised an important issue by discussing gender differences in outcomes of calcitonin
Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial
The Lancet Neurology 2024 Feb 13:S1474-4422(24)00025-5. doi: 10.1016/S1474-4422(24)00025-5. Cristina Tassorelli, Krisztián Nagy, Patricia Pozo-Rosich, Michel Lanteri-Minet, Sara Sacco, Tomáš Nežádal, Hua Guo, Rosa De Abreu Ferreira, Giovanna Forero, Joel M Trugman Abstract Background: Atogepant, an oral calcitonin gene-related peptide receptor antagonist, has been approved for the preventive treatment of